MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-09-2023
NeuBase Therapeutics Revenue 2011-2026 | NBSE
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue NeuBase Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -416 K | -225 K | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -225 K | -416 K | -320 K |
Quarterly Revenue NeuBase Therapeutics
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | -416 K | -98.8 K | -37.2 K | -36.1 K | -25.4 K | -219 K | -101 K | -25.4 K | -24.5 K | - | - | -24.5 K | - | - | - | - | - | - | - | - | - | - | - | - | - | -97.9 K | -30.1 K | -41.2 K | -26.6 K | - | - | -26.6 K | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -24.5 K | -416 K | -82 K |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M |  Germany |
 |
AbCellera Biologics
ABCL
|
75.1 M | $ 3.55 | -0.42 % | $ 1.06 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
118 M | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
100 M | - | 4.01 % | $ 150 M | Canada |
 |
Advaxis
ADXS
|
13 K | - | -9.65 % | $ 45.9 M | USA |
 |
AC Immune SA
ACIU
|
27.3 M | $ 3.24 | 3.35 % | $ 229 M |  Schweiz |
 |
I-Mab
IMAB
|
88 M | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | USA |
 |
AgeX Therapeutics
AGE
|
142 K | - | -10.17 % | $ 12.2 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | USA |
 |
Albireo Pharma
ALBO
|
40.6 M | - | -0.23 % | $ 916 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | USA |
 |
ADC Therapeutics SA
ADCT
|
2.34 M | $ 4.14 | -1.9 % | $ 105 M | Schweiz |
 |
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
Aptorum Group Limited
APM
|
912 K | $ 0.82 | 4.22 % | $ 4.47 M | China |
 |
argenx SE
ARGX
|
36.4 M | $ 714.55 | 1.6 % | $ 25 B |  Niderland |
 |
Adverum Biotechnologies
ADVM
|
1 M | - | - | $ 86.2 M | USA |
 |
Ascendis Pharma A/S
ASND
|
720 M | $ 231.26 | 0.1 % | $ 5 B |  Danmark |
 |
Alterity Therapeutics Limited
ATHE
|
109 K | $ 3.4 | -5.82 % | $ 8.18 B |  Australia |
 |
Atea Pharmaceuticals
AVIR
|
351 M | $ 6.09 | 0.66 % | $ 496 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
325 K | - | - | $ 26.5 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
82 M | $ 6.6 | -0.45 % | $ 181 M |  Israel |
 |
Институт стволовых клеток человека
ISKJ
|
1.08 B | - | - | - |  Russia |
 |
BioCardia
BCDA
|
477 K | $ 1.37 | 7.87 % | $ 29 M | USA |
 |
Athersys
ATHX
|
5.51 M | - | 3.77 % | $ 22.4 M | USA |
 |
Acer Therapeutics
ACER
|
1.26 M | - | 2.71 % | $ 14 M | USA |
 |
Aeterna Zentaris
AEZS
|
9.59 M | - | 5.93 % | $ 314 M | Canada |
 |
AlloVir
ALVR
|
165 K | - | 4.14 % | $ 49.1 M | USA |
 |
Catalyst Biosciences
CBIO
|
117 M | $ 11.29 | -2.5 % | $ 1.01 B | USA |
 |
Anika Therapeutics
ANIK
|
167 M | $ 14.61 | 1.71 % | $ 214 M | USA |
 |
Aptinyx
APTX
|
1 M | - | -39.0 % | $ 4.57 M | USA |
 |
AVEO Pharmaceuticals
AVEO
|
42.3 M | - | - | $ 521 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
692 K | - | - | $ 7.46 M | Israel |
 |
BioNTech SE
BNTX
|
482 M | $ 92.9 | 2.61 % | $ 27.2 B | Germany |
 |
Aytu BioScience
AYTU
|
66.4 M | $ 2.64 | - | $ 16.6 M | USA |
 |
CorMedix
CRMD
|
312 M | $ 6.57 | 0.46 % | $ 473 K | USA |
 |
Burford Capital Limited
BUR
|
330 M | $ 8.24 | 2.36 % | $ 1.33 B | Britain |
 |
Autolus Therapeutics plc
AUTL
|
242 K | $ 1.5 | -0.99 % | $ 383 M | Britain |
 |
CureVac N.V.
CVAC
|
48.9 M | - | - | $ 867 M | Germany |